LY-518674

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameLY-518674
Drug Alias NameLY-518674LY-674
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsHypercholesterolemiaDyslipidemiasMetabolic Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSweden
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLigand Pharmaceuticals IncEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaDyslipidemiasMetabolic Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksN/A